

NOTICE OF MEETING

NOTICE IS GIVEN that an annual general and special meeting (the “**Meeting**”) of the holders of common shares (“**Mydecine Shareholders**”) of Mydecine Innovations Group Inc. (“**Mydecine**”) will be held virtually at <https://virtual-meetings.tsxtrust.com/1220> (password: mydecine2021) on September 20, 2021 at 11:00 a.m. (Pacific time) for the following purposes:

1. to receive Mydecine’s audited financial statements for the financial year ended December 31, 2020 and the auditor’s report thereon;
2. to appoint MNP LLP, as Mydecine’s auditor for the ensuing fiscal year and to authorize the directors to set the auditor’s remuneration;
3. to set the number of directors at seven (7);
4. to elect the directors of Mydecine for the ensuing year;
5. to approve the New Mydecine Equity Incentive Plan;
6. to consider pursuant to an interim order of the Supreme Court of British Columbia dated August 20, 2021 (the “**Mydecine Interim Order**”) and, if thought advisable, to pass, with or without amendment, a special resolution (the “**Arrangement Resolution**”) approving an arrangement (the “**Arrangement**”) under Section 288 of the *Business Corporations Act* (British Columbia), the full text of which resolution is set forth in Appendix A to the accompanying Management Information Circular (the “**Circular**”);
7. to approve the Spinco Stock Option Plan; and
8. to transact such further or other business as may properly come before the shareholders at the Meeting or any adjournments thereof.

The Circular provides additional information relating to the matters to be addressed at the Meeting, including the Arrangement, and is deemed to form part of this Notice. Any capitalized terms used but not defined herein shall have the meanings ascribed to them in the Circular.

In order to address the public health impact of the coronavirus disease (COVID-19) pandemic, mitigate health and safety risks to Mydecine’s shareholders, employees and other stakeholders, and abide by government guideline limiting indoor public events, Mydecine will hold a virtual-only Meeting via live webcast, hosted by TSX Trust. Mydecine Shareholders will have an equal opportunity to participate in the Meeting online, regardless of geographic location, as well as to ask questions and vote on certain topics. Non-registered (or beneficial) shareholders who have not duly appointed themselves as proxyholder will be able to participate in the Meeting as guests, but guests will not be able to vote or speak at the Meeting. Mydecine Shareholders will not be able to attend Meeting physically. A summary of the information shareholders and proxyholders will need to attend the Meeting online is provided in this Circular attached to this Notice of Meeting.

A Mydecine Shareholder who intends to exercise a right of dissent should carefully consider and comply with the provisions of sections 237 to 247 of the *Business Corporations Act* (British Columbia), and should seek independent legal advice. Failure to strictly comply with the provisions of those sections and to adhere to the procedures established therein may result in the loss of all rights thereunder.

The Aequitas Neo Exchange has neither reviewed nor approved the disclosure in the Circular.

DATED at Vancouver, British Columbia this 23rd day of August, 2021.

**BY ORDER OF THE BOARD OF DIRECTORS OF
MYDECINE INNOVATIONS GROUP INC.**

“David Joshua Barch”
Chief Executive Officer